Internal Medicine - Issue 12/2018

Guidelines

1124
A summary of the EAS consensus concerning the causal relationship between low-density lipoproteins and atherosclerotic cardiovascular diseases, prepared by the Board of the Czech Society for Atherosclerosis

Vladimír Soška, David Karásek, Vladimír Bláha, Renata Cífková, Tomáš Freiberger, Pavel Kraml, Jan Piťha, Hana Rosolová, Tomáš Štulc, Zuzana Urbanová, Michal Vrablík


News

1131
Consensus statement of professional associations on prescribing of PCSK9-inhibitors

Richard Češka, Miloš Táborský, Michal Vrablík


Actualities

1137
Comments on the most important and recent studies involving PCSK9i

Richard Češka


1142
Inflammation and atherosclerosis

Rudolf Poledne, Ivana Králová Lesná

1148
Bilirubin: from an unimportant waste product to important myocardial infarction predictor

Jaroslav A. Hubáček, Libor Vítek

1153
“The higher the better” seems to be no longer true for HDL-cholesterol

Hana Rosolová

1156
Current views on metabolic syndrome

Štěpán Svačina

1160
Lipoprotein(a) – the cardiovascular risk factor: significance and therapeutic possibilities

Vladimír Bláha

1169
Why not to interfere with LDL-cholesterol freefall and why not to talk badly about statins

Jan Piťha

1177
Combined lipid-lowering therapy

David Karásek

1186
PCSK9 inhibitors and diabetes mellitus

Branislav Vohnout, Jana Lisičanová, Andrea Havranová


Original Contributions

1190
The changes in cardiovascular prevention practice between 1995–2017 in the Czech Republic: a comparison of EUROASPIRE I, II, III, IV and V study

Otto Mayer Jr, Jan Bruthans, Martina Rychecká Za Investigátory Studií Euroaspire I V V České Republice


Login
Forgotten password

Don‘t have an account?  Create new account

Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account